Multiple myeloma

An update

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Multiple myeloma is a rare, largely incurable malignant disease of plasma cells. Patients usually present with hypercalcemia, renal insufciency, anemia and/or lytic bony lesions along with a monoclonal protein in the serum and/or urine in addition to an increase in the number of clonal plasma cells in the bone marrow. Patients with myeloma live on an average for fve to seven years, with their survival dependent on the presence or absence of diferent prognostic markers. Treatment of younger ft patients is with induction therapy consisting of steroids with one or more novel anti-myeloma agents followed by high dose melphalan and autologous stem cell transplantation, while older and less ft patients are treated with melphalan-based combination chemotherapy. Supportive care is of paramount importance and includes the use of bisphosphonates, prophylactic antibiotics, thrombosis prophylaxis and the use of hematopoietic growth factors along with the treatment of complications of disease and its therapy. As more progress is being made and deeper responses are being attained, the disease might turn into a potentially curable one in the near future.

Original languageEnglish
Pages (from-to)3-11
Number of pages9
JournalOman Medical Journal
Volume28
Issue number1
DOIs
Publication statusPublished - 2013

Fingerprint

Multiple Myeloma
Melphalan
Plasma Cells
Antibiotic Prophylaxis
Diphosphonates
Hypercalcemia
Stem Cell Transplantation
Therapeutics
Combination Drug Therapy
Anemia
Blood Proteins
Intercellular Signaling Peptides and Proteins
Thrombosis
Bone Marrow
Steroids
Urine
Kidney
Survival

Keywords

  • Monoclonal gammopathy
  • Multiple myeloma
  • Myeloma
  • Plasma cell dyscrasia
  • Plasma cell myeloma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Multiple myeloma : An update. / Al-Farsi, Khalil.

In: Oman Medical Journal, Vol. 28, No. 1, 2013, p. 3-11.

Research output: Contribution to journalReview article

Al-Farsi, Khalil. / Multiple myeloma : An update. In: Oman Medical Journal. 2013 ; Vol. 28, No. 1. pp. 3-11.
@article{7edc3616165f41faa6f279b0d7370466,
title = "Multiple myeloma: An update",
abstract = "Multiple myeloma is a rare, largely incurable malignant disease of plasma cells. Patients usually present with hypercalcemia, renal insufciency, anemia and/or lytic bony lesions along with a monoclonal protein in the serum and/or urine in addition to an increase in the number of clonal plasma cells in the bone marrow. Patients with myeloma live on an average for fve to seven years, with their survival dependent on the presence or absence of diferent prognostic markers. Treatment of younger ft patients is with induction therapy consisting of steroids with one or more novel anti-myeloma agents followed by high dose melphalan and autologous stem cell transplantation, while older and less ft patients are treated with melphalan-based combination chemotherapy. Supportive care is of paramount importance and includes the use of bisphosphonates, prophylactic antibiotics, thrombosis prophylaxis and the use of hematopoietic growth factors along with the treatment of complications of disease and its therapy. As more progress is being made and deeper responses are being attained, the disease might turn into a potentially curable one in the near future.",
keywords = "Monoclonal gammopathy, Multiple myeloma, Myeloma, Plasma cell dyscrasia, Plasma cell myeloma",
author = "Khalil Al-Farsi",
year = "2013",
doi = "10.5001/omj.2013.02",
language = "English",
volume = "28",
pages = "3--11",
journal = "Oman Medical Journal",
issn = "1999-768X",
publisher = "Oman Medical Specialty Board",
number = "1",

}

TY - JOUR

T1 - Multiple myeloma

T2 - An update

AU - Al-Farsi, Khalil

PY - 2013

Y1 - 2013

N2 - Multiple myeloma is a rare, largely incurable malignant disease of plasma cells. Patients usually present with hypercalcemia, renal insufciency, anemia and/or lytic bony lesions along with a monoclonal protein in the serum and/or urine in addition to an increase in the number of clonal plasma cells in the bone marrow. Patients with myeloma live on an average for fve to seven years, with their survival dependent on the presence or absence of diferent prognostic markers. Treatment of younger ft patients is with induction therapy consisting of steroids with one or more novel anti-myeloma agents followed by high dose melphalan and autologous stem cell transplantation, while older and less ft patients are treated with melphalan-based combination chemotherapy. Supportive care is of paramount importance and includes the use of bisphosphonates, prophylactic antibiotics, thrombosis prophylaxis and the use of hematopoietic growth factors along with the treatment of complications of disease and its therapy. As more progress is being made and deeper responses are being attained, the disease might turn into a potentially curable one in the near future.

AB - Multiple myeloma is a rare, largely incurable malignant disease of plasma cells. Patients usually present with hypercalcemia, renal insufciency, anemia and/or lytic bony lesions along with a monoclonal protein in the serum and/or urine in addition to an increase in the number of clonal plasma cells in the bone marrow. Patients with myeloma live on an average for fve to seven years, with their survival dependent on the presence or absence of diferent prognostic markers. Treatment of younger ft patients is with induction therapy consisting of steroids with one or more novel anti-myeloma agents followed by high dose melphalan and autologous stem cell transplantation, while older and less ft patients are treated with melphalan-based combination chemotherapy. Supportive care is of paramount importance and includes the use of bisphosphonates, prophylactic antibiotics, thrombosis prophylaxis and the use of hematopoietic growth factors along with the treatment of complications of disease and its therapy. As more progress is being made and deeper responses are being attained, the disease might turn into a potentially curable one in the near future.

KW - Monoclonal gammopathy

KW - Multiple myeloma

KW - Myeloma

KW - Plasma cell dyscrasia

KW - Plasma cell myeloma

UR - http://www.scopus.com/inward/record.url?scp=84873282340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873282340&partnerID=8YFLogxK

U2 - 10.5001/omj.2013.02

DO - 10.5001/omj.2013.02

M3 - Review article

VL - 28

SP - 3

EP - 11

JO - Oman Medical Journal

JF - Oman Medical Journal

SN - 1999-768X

IS - 1

ER -